These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

717 related articles for article (PubMed ID: 23399552)

  • 21. Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR).
    Lanas A; Goldstein JL; Chan FK; Wilcox CM; Peura DA; Li C; Sands GH; Scheiman JM
    Aliment Pharmacol Ther; 2012 Sep; 36(5):485-92. PubMed ID: 22804104
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
    Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
    Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the incidence rates of selected gastrointestinal events reported for patients prescribed celecoxib and meloxicam in general practice in England using prescription-event monitoring (PEM) data.
    Layton D; Hughes K; Harris S; Shakir SA
    Rheumatology (Oxford); 2003 Nov; 42(11):1332-41. PubMed ID: 12810929
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Celecoxib, a cyclooxygenase-2 inhibitor, improved upper gastrointestinal lesions in rheumatoid arthritis patients as assessed by endoscopic evaluation.
    Tsuji S; Miyoshi H; Tomita T; Nakase T; Hamada M; Oomae T; Tsumoto C; Hirata Y; Iguchi M; Edogawa S; Kawai H; Yoshikawa H
    Mod Rheumatol; 2012 Jun; 22(3):353-62. PubMed ID: 21904784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial.
    Simon LS; Weaver AL; Graham DY; Kivitz AJ; Lipsky PE; Hubbard RC; Isakson PC; Verburg KM; Yu SS; Zhao WW; Geis GS
    JAMA; 1999 Nov; 282(20):1921-8. PubMed ID: 10580457
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial.
    Goldstein JL; Cryer B; Amer F; Hunt B
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1167-74. PubMed ID: 17916545
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
    Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced risk of upper gastrointestinal ulcer complications with celecoxib, a novel COX-2 inhibitor.
    Goldstein JL; Silverstein FE; Agrawal NM; Hubbard RC; Kaiser J; Maurath CJ; Verburg KM; Geis GS
    Am J Gastroenterol; 2000 Jul; 95(7):1681-90. PubMed ID: 10925968
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-steroidal anti-inflammatory drugs use and risk of upper gastrointestinal adverse events in cirrhotic patients.
    Lee YC; Chang CH; Lin JW; Chen HC; Lin MS; Lai MS
    Liver Int; 2012 May; 32(5):859-66. PubMed ID: 22226322
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haemoglobin decreases in NSAID users over time: an analysis of two large outcome trials.
    Goldstein JL; Chan FK; Lanas A; Wilcox CM; Peura D; Sands GH; Berger MF; Nguyen H; Scheiman JM
    Aliment Pharmacol Ther; 2011 Oct; 34(7):808-16. PubMed ID: 21810115
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Persistence with non-selective NSAIDs and celecoxib among patients with gastroesophageal reflux disease and osteoarthritis or rheumatoid arthritis.
    Cryer B; Luo X; Assaf AR; Sands G; Mardekian J
    Curr Med Res Opin; 2011 Feb; 27(2):295-302. PubMed ID: 21142617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Upper gastrointestinal tolerability of celecoxib, a COX-2 specific inhibitor, compared to naproxen and placebo.
    Bensen WG; Zhao SZ; Burke TA; Zabinski RA; Makuch RW; Maurath CJ; Agrawal NM; Geis GS
    J Rheumatol; 2000 Aug; 27(8):1876-83. PubMed ID: 10955327
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
    Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
    J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonsteroidal anti-inflammatory drugs and upper and lower gastrointestinal mucosal damage.
    Sostres C; Gargallo CJ; Lanas A
    Arthritis Res Ther; 2013; 15 Suppl 3(Suppl 3):S3. PubMed ID: 24267289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systematic review and meta-analysis of information from company clinical trial reports.
    Moore RA; Derry S; Makinson GT; McQuay HJ
    Arthritis Res Ther; 2005; 7(3):R644-65. PubMed ID: 15899051
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of the selective cyclooxygenase-2 inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan.
    Sakamoto C; Soen S
    Digestion; 2011; 83(1-2):108-23. PubMed ID: 21042022
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclooxygenase-2 specific inhibitors and upper gastrointestinal tolerability in patients with osteoarthritis receiving concomitant low dose aspirin: pooled analysis of 2 trials.
    Goldstein JL; Bello AE; Spalding W; Suh S; Fort JG
    J Rheumatol; 2005 Jan; 32(1):111-7. PubMed ID: 15630735
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of celecoxib in the treatment of acute pain due to ankle sprain in a Latin American and Middle Eastern population.
    Cardenas-Estrada E; Oliveira LG; Abad HL; Elayan F; Khalifa N; El-Usseini T
    J Int Med Res; 2009; 37(6):1937-51. PubMed ID: 20146894
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
    Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
    Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.